The Duke Sarcoma Research Program uses a multidisciplinary, patient-centric approach to diagnose and treat bone and soft-tissue sarcomas. Through unsurpassed clinical care, personalized treatment planning and delivery, and state-of-the-art basic scientific and clinical research, the program is the center of excellence for the treatment of sarcoma in the Southeast.
The leaders of the program have created a robust basic, translational and clinical research portfolio. They want to have a clinical trial option for every patient.
Researchers in this program have conducted and are conducting several sarcoma-specific clinical trials, including pharmaceutically-sponsored, investigator-initiated and cooperative group trials. Their basic science research centers on mouse models of soft tissue sarcoma and rhabdomyosarcoma developed by members of the Duke Sarcoma Research Program.
Strengths of the program include:
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More